There is one clinical trial.
To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS patients infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Description: improvement of lung injury score (LIS), 0-16 points, severity increasing with higher pointsMeasure: lung injury score Time: day 10
Description: D-dimers blood levelsMeasure: D-dimers Time: day 0, 1, 2, 3, 10 and 15
Description: distribution of phenotypes of immune cellsMeasure: phenotype Time: day 0, 1, 2, 3, 10 and 15
Description: Levels of specialized pro-resolving lipid mediators within alveolar macrophages and bronchoalveolar lavageMeasure: pro-resolving lipid mediators Time: day 0, 1, 2, 3, 10 and 15
Description: Cytokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusionsMeasure: cytokines Time: day 0, 1, 2, 3, 10 and 15
Description: Chemokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusionsMeasure: chemokines Time: day 0, 1, 2, 3, 10 and 15
Description: Survival at 10 days and 28 daysMeasure: Survival Time: day 10 and 28
Description: Time to removal of endotracheal tubeMeasure: extubation Time: day 28
Description: lymphocyte subpopulations in peripheral blood by flow cytometry prior and after MSC infusion (day 0,3,5,10)Measure: lymphocyte subpopulations Time: day 0, 3, 5 and 10
Description: evaluate SARS-CoV-2-specific antibody titers in the serum of patients prior and post MSC infusion.Measure: SARS-CoV-2-specific antibody titers Time: day 0, 5 and 10
Description: evaluate levels of complement molecules (C5-C9) in the serum of patients prior and post MSC infusionMeasure: complement molecules (C5-C9) Time: day 0, 5 and 10
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports